Skip to main content
AKTS logo

Aktis Oncology, Inc.

AKTSNASDAQHealthcareBiotechnology

$15.73Today:- (-)

As of Oct 26, 2026 close

Market cap
$869.87M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$14.72$34.19
Volume (live)
-
Avg. volume (3M)
460.35K

Aktis Oncology (AKTS) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Aktis Oncology used $64.13M of cash in operating activities and spent $9.58M on capital expenditures. That left free cash flow of −$73.71M.

Aktis Oncology Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Aktis Oncology, Inc. (AKTS) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022
Period endingDec 2025Dec 2024Dec 2023Dec 2022
Operating Activities
Net Income-63.73-43.98-28.64-17.93
Depreciation & Amortization2.331.581.120.45
Stock Based Compensation5.132.261.480.70
Change in Working Capital-3.2358.98-0.02-1.14
Change in Accounts Receivable1.03-0.86-0.260.00
Change in Accounts Payable-0.040.360.660.00
Change in Other Working Capital0.11-2.05-0.45-1.14
Other Operating Activities-4.62-4.07-3.95-0.20
Net Cash from Operating Activities-64.1314.76-30.00-18.13
Investing Activities
Capital Expenditures-9.58-2.86-3.76-2.31
Purchases of Investments-193.87-288.40-145.810.00
Sales/Maturities of Investments269.42100.8680.690.00
Other Investing Activities0.000.000.060.00
Net Cash from Investing Activities65.96-190.40-68.83-2.31
Financing Activities
Common Stock Issued0.340.180.000.00
Other Financing Activities-1.55-1.900.00-0.15
Net Cash from Financing Activities-1.21183.280.00119.98
Summary
Net Change in Cash0.637.65-98.8399.55
Cash at Beginning of Period38.3130.66129.4929.94
Cash at End of Period38.9338.3130.66129.49
Free Cash Flow-73.7111.90-33.77-20.43

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Aktis Oncology Cash Flow

What is Aktis Oncology's free cash flow?

Aktis Oncology had negative free cash flow of $73.71M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$64.13M minus $9.58M of capital expenditures.

How much does Aktis Oncology spend on capital expenditures?

Aktis Oncology spent $9.58M on capital expenditures in fiscal 2025, compared with $2.86M a year earlier.

Does Aktis Oncology pay dividends or buy back shares?

Aktis Oncology's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition